Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

2760 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-08

Study Completion Date

2017-12-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate and valuate the immunogenicity and safety of the 13-valent pneumococcal polysaccharide conjugate vaccine in 2-71 months old healthy infants and toddlers (the youngest could be 6 weeks old)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

NCT05092386

Pneumococcal Infections

COMPLETED PHASE1

Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine

NCT06617715

Pneumococcal Infectious Disease

RECRUITING PHASE3

Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine

NCT06703203

Pneumococcal Vaccines

ENROLLING_BY_INVITATION PHASE1/PHASE2

Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants

NCT05759520

Streptococcus Pneumoniae Infection

ACTIVE_NOT_RECRUITING PHASE3

PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months

NCT07333352

Pneumococcal Infectious Disease

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diseases Caused by Streptococcus Pneumoniae Serotypes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Arm

7-valent pneumococcal conjugate vaccine

Group Type ACTIVE_COMPARATOR

7-valent pneumococcal conjugate vaccine

Intervention Type BIOLOGICAL

Test Arm

13-valent pneumococcal conjugate vaccine

Group Type EXPERIMENTAL

13-valent pneumococcal polysaccharide conjugate vaccine

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

7-valent pneumococcal conjugate vaccine

Intervention Type BIOLOGICAL

13-valent pneumococcal polysaccharide conjugate vaccine

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 2-71 months (the youngest could be 6 weeks old) infants or toddlers which are positively healthy based on the medical history, the physical examination and the judgment of the investigator;
* The statutory guardian (or the consignor) of the subject agree his/her child participate in the study, and is willing to sign the informed consent form;
* The subject and his/her statutory guardians (or the consignor) are able to comply with the requests of the clinical study protocol;
* Never be immunized with any pneumococcus vaccine, and didn't get immunization with any other preventive product in the past 10 days (didn't get immunized with attenuated live vaccine in the past 14 days);
* The auxillary temperature ≤37℃.

Exclusion Criteria

* Has already been immunized with pneumococcus vaccine no matter it is experimental or marketed;
* With the history of invasive disease caused by streptococcus pneumonia by culture;
* With the history of serious allergy to any vaccine or drug, has got fever higher than 39℃ related to immunization with preventive biological product;
* Infant that the birth weight is lighter than 2.5 kg;
* With the history or the family history of seizure, epilepsy, cerebropathy and psychosis ;
* Infant with the abnormal labor (difficult labor, deliver with apparatus) or with the history of asphyxia or nervous damage;
* With the history of thrombocytopenia or other coagulation disorders by definite diagnosis;
* Infant or toddler with pathological jaundice by diagnosis;
* Be known with or suspected with immunological dysfunction, including immunosuppressive therapy (radiotherapy, chemotherapy, corticosteroid hormone, antimetabolites, cytotoxic drug), HIV infection etc. ;
* Be known with serious congenital malformation or serious chronic disease; suffer from congenital malformation or be diagnosed with serious chronic disease (eg. Down syndrome, diabetes mellitus, sickle cell anemia or nervous disease, Guillain-Barre syndrome);
* Be known with or suspected with diseases including: disease of respiratory system, acute infection or the active period of chronic disease, serious cardiovascular disease, hepatic-nephrotic disease, malignant tumor, skin disease;
* Has taken blood product or globulin (the hepatitis B immune globulin is allowed);
* Be participating in other clinical trials;
* Any other situation which is considered to influence the evaluation of the study by investigators .

Minimum Eligible Age

2 Months

Maximum Eligible Age

71 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes